IQV IQVIA Holdings Inc

IQVIA Named to FORTUNE’s 2018 List of “World’s Most Admired Companies”

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has once again been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA received the distinction in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks in quality of management, value as a long-term investment, effectiveness in conducting business globally and wise use of corporate assets.

“We’re thrilled to be included on FORTUNE’s list of the World’s Most Admired Companies. This recognition is a testament to the dedication of our 55,000+ employees who work every day to ignite advances in data science and human science to transform healthcare decision making,” said IQVIA Chairman and CEO Ari Bousbib. “We are excited to continue to help clients, partners and patients tap into advances in analytics and technologies to find new ways to make healthcare work better for everyone.”

FORTUNE’s World’s Most Admired Companies list is the definitive report card on corporate reputations. Since 1997, FORTUNE has identified, selected and ranked the World’s Most Admired Companies, uncovering the business practices that make these companies highly regarded among their peers.

Most Admired Company Survey Methodology

In compiling the Most Admired list, FORTUNE survey partner Korn Ferry Hay Group surveyed 680 companies from 28 countries asking executives, directors and analysts to rate companies within their own industry on nine reputation drivers considered to be crucial to a company’s global success. These drivers include financial soundness, long-term investment value, people management, social responsibility, use of assets, quality of management, quality of products/services, innovation and global competitiveness. A company’s score must rank in the top half of its industry survey to be listed.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.

IQVIAFIN

Click here to subscribe to Mobile Alerts for IQVIA.

EN
19/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IQVIA Holdings Inc

IQVIA Holdings Inc: 1 director

A director at IQVIA Holdings Inc sold 1,300 shares at 246.330USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Moody's assigns Baa3 rating to IQVIA's new senior secured notes, Ba2 r...

Moody's Investors Service (Moody's) assigned Baa3 rating to the proposed US dollar-denominated senior secured notes, and Ba2 rating to the proposed senior unsecured notes of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba1 corporate family rating (CFR), Ba1-P...

IQVIA HOLDINGS sees a downgrade to Slightly Negative on account of les...

The independent financial analyst theScreener just lowered the general evaluation of IQVIA HOLDINGS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was US...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 12 07

Freeport-McMoRan (FCX) is one of the best-positioned copper miners to benefit from the various megatrends pushing copper demand higher. Uniform Accounting highlights that the market is significantly mispricing the value of Freeport's production capabilities, signaling the potential for equity upside. With trends like the IoT and EVs driving stronger demand for precious metals, copper producers like Freeport are well positioned for a boost in profitability. Additionally, Freeport has the po...

Valens Research
  • Valens Research

IQV - Embedded Expectations Analysis - 2021 12 02

IQVIA Holdings (IQV) currently trades above corporate and historical averages relative to Uniform earnings, with a 28.2x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to recover to 62%, accompanied by 12% Uniform asset growth. Similarly, analysts expect Uniform ROA to improve to 58% by 2022, accompanied by 24% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $414, representing significant potenti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch